Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
September 2025
The worldwide tomo mammography market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. This growth is driven by emerging trends and strong demand across key sectors.
The wide popularity of digital breast tomosynthesis (DBT) or tomo mammography for breast cancer screening is due to its potential accuracy, especially in women with dense breasts. The certified mammography facilities in the U.S. drive the huge improvements over traditional 2D digital mammography. The rising incidence of breast cancer and the growing patient awareness expand the global tomo mammography market. Advanced healthcare infrastructure, high screening rates, and supportive reimbursement policies accelerate the market in countries like North America and the Asia Pacific.
The tomo mammography market refers to digital breast tomosynthesis (DBT) systems and associated products, software, and services that are used to produce three-dimensional (slice-based) mammographic images for breast cancer screening, diagnostic assessment, and image-guided procedures. It covers DBT-capable mammography units (standalone DBT, DBT + 2D synthesized/FFDM combos), detectors, reconstruction and AI/reading software, biopsy guidance accessories, consumables, installations, maintenance, and clinical workflow/integration in hospitals, imaging centers, and mobile screening units.
The BCRF supports more than 260 scientists at the leading medical and academic institutions across 16 countries to enhance breast cancer screening and early detection. For instance, in September 2024, the Breast Cancer Research Foundation (BCRF) announced a significant investment of $70.3 million in research projects and scientific grants to over 260 researchers for the treatment, prevention, and end of breast cancer.
AstraZeneca aims to transform breast cancer care for underserved patient populations. For instance, in April 2024, AstraZeneca funded the initiative named ‘The Powering Breast Cancer Progress (PBCP) grant program which is supported by ‘Charities Aid Foundation’ (CAF) to improve health outcomes for underserved patient populations.
Artificial intelligence creates several opportunities to enhance the digital breast tomosynthesis (DBT) and mitigate its limitations. AI algorithms are significant in the screening and diagnostic phases of breast cancer detection and characterization. AI can reduce the time required for radiologists to interpret images and streamline the workflow. AI enhances lesion visibility in synthetic 2D digital mammography images.
What are the Major Drifts in the Tomo Mammography Market?
The incorporation of more sensitive sensors and more intelligent software by the latest generation of machines allows the next-generation imaging. There is an integral role of AI in smarter cancer spotting by identifying patterns, reducing errors, and giving alert to unusual areas. Tomosynthesis or 3D mammography can potentially capture dozens of X-ray images from multiple angles and create a 3D picture of the breast.
What are the Potential Challenges in the Tomo Mammography Market?
The integration of various advanced technologies like AI into clinical workflows faces numerous challenges related to the urgent need for professional training, unexpected errors, and ethical concerns. The other key challenges are associated with technological concerns, reproducibility, and trust issues. Moreover, there are certain ethical, legal, and societal concerns with the implementation of technologies in breast cancer screening programs.
What is the Future of the Tomo Mammography Market?
Significant opportunities arise with technological expansion and innovations. These include the emergence of AI-powered solutions, improved visualization, cloud and telemedicine platforms, and portable and mobile units. The diagnostic imaging centers are the fastest-growing end users for digital breast tomosynthesis (DBT). They offer cost-effective and efficient outpatient imaging services. The adoption of cloud-based DBT platforms by a large number of clinics creates remarkable opportunities for teleradiologists to interpret breast imaging remotely.
The DBT + 2D combo systems segment dominated the market in 2024, owing to the advantages of these systems in improved cancer detection. They are popular and efficient due to advancements over conventional 2D mammography. They offer better image quality, enhanced features, and cost-effectiveness.
The standalone DBT with synthesized 2D & CEM-enabled DBT segment is expected to grow at the fastest CAGR in the market during the forecast period due to the benefits such as reduced tissue overlap, increased cancer detection rates, decreased false positives, and better lesion characterization. The synthesized 2D mammography results in reduced radiation dose, comparable accuracy, and similar workflow and interpretation. The contrast-enhanced mammography (CEM) results in increased sensitivity and specificity and enables CEM-guided biopsy.
The CMOS flat-panel detectors segment dominated the market in 2024, owing to the better image quality at high doses, higher spatial resolution, increased speed, and faster workflow. They produce optimal image quality for both higher-dose standard mammograms and low-dose tomosynthesis acquisitions in a single system. They produce clearer images, which are important for dynamic procedures like tomosynthesis, where images are captured at rapid succession rates.
The advanced CMOS + high DQE detectors & detector upgrade kits segment is estimated to grow at the fastest rate in the market during the predicted timeframe due to higher accuracy in pinpointing abnormalities and better detection of small cancers. They offer quantum efficiency, smart dose control, and synthetic 2D images. They result in enhanced workflow and improved patient experience through faster results and reduced need for additional imaging.
The reconstruction & synthetic 2D generation segment dominated the market in 2024, owing to the excellence of synthetic 2D generation in terms of reduced patient discomfort and improved diagnostic performance. It enables high diagnostic accuracy for dense breasts and significant clinical and logistical advantages over traditional mammography. It enables reduced patient anxiety and decreased radiation exposure.
The AI-based CAD and triage/prioritization + analytics segment is anticipated to grow at a notable rate in the market during the upcoming period due to the benefits of AI-based CAD and diagnosis, which include improved diagnostic performance, reduced cognitive errors, and better detection in breast cancers. They offer streamlined workflow, reduced workload, and faster time to diagnosis. AI-based analytics provides personalized screening recommendations, enabling quality control and process improvement.
The hospital radiology departments & large imaging centers segment dominated the market in 2024, owing to the key role of hospital radiology departments in comprehensive care, access to prior records, additional technologies, and problem-solving of complex cases. The large imaging centers enable streamlined appointments, patient-centric design, and efficient workflow. The tomo mammography is beneficial in both settings for improved cancer detection, reduced false positives, better lesion characterization, and earlier cancer detection.
The mobile screening units & community screening programs segment is predicted to grow at a rapid rate in the market during the studied period due to increased accessibility, reduced health disparities, and convenience offered by mobile and community screening programs. They also offer improved outreach, education, and effective engagement for under-screened populations. The tomo mammography in this setting benefits from more accurate cancer detection, improved diagnostic clarity, detection of smaller cancers, and high-quality imaging.
The standalone + PACS-integrated systems segment dominated the market in 2024, owing to superior image display, advanced visualization tools, enhanced specificity, and optimal user experience. The PACS integration results in streamlined workflow, centralized data management, improved data accessibility, and enhanced reporting. It results in scalability, disaster recovery, reduced errors, and reduced duplication.
The deeply integrated AI + RIS/PACS solutions with automated triage & reporting segment is expected to grow at the fastest CAGR in the market during the forecast period due to the potential of these solutions for workflow and efficiency, enabling streamlined reporting, reduced reading time, and enhanced consistency. They are beneficial for diagnostic performance through improved accuracy in the detection of dense breast cancers. They are also advantageous for patient outcomes and patient experience due to faster time to diagnosis, decreased patient anxiety, and proactive care planning.
North America dominated the market in 2024, owing to the early adoption and reimbursement for DBT screening. In September 2024, the Radiological Society of North America (RSNA) reported that its 10-year study shows the effectiveness of tomosynthesis in improving breast cancer detection.
iCAD, Inc. remains a global leader in clinically proven AI-powered cancer detection solutions, which has planned to display its breakthrough innovations in breast health AI technologies at the 2024 annual meeting of the Radiological Society of North America (RSNA). Moreover, iCAD, Inc. made a partnership with Cascaid Health at the RSNA 2024 by advancing the fight against breast cancer with FDA-approved and next-generation AI solutions. In February 2024, the National Institutes of Health (NIH) launched a research network for the evaluation of emerging cancer screening technologies.
This cancer screening research network (CSRN) supports the cancer moonshot initiative of the Biden-Harris Administration and helps in the early investigation of cancers.
In July 2025, Penn Medicine, located in Pennsylvania, U.S., launched a mobile mammography program to provide breast cancer screenings throughout the region.The National Cancer Institute (NCI) recommends breast cancer screening, which includes mammography, ultrasound, MRI, and other tests. The U.S. Food and Drug Administration (FDA) introduced the Mammography Quality Standards Act (MQSA) and the MQSA program to ensure equal access to quality mammography for the early detection of breast cancers.
The Government of Canada reported the improvements in breast cancer screening research and its implementation in Canada. The Canadian Association of Radiologists is committed to improving Canadian radiology and patient outcomes. The Canadian Organization of Medical Physicists designed and introduced the mammography workshop through cutting-edge research and new imaging technologies.
The Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period, driven by the expansion of screening services, rising awareness, and growth in private imaging. The AI-driven diagnostics introduce operational efficiency and improved clinical outcomes across the Asia Pacific. The advanced technologies are accelerating tumor diagnosis in biopsy tissues. There is a high demand for personalized and efficient healthcare, and the MedTech industry is booming in this region. The Asia Pacific Medical Technology Association (APACMed), in collaboration with KPMG, surveyed global practices in healthcare and consulted with stakeholders in the MedTech industry. It is expected that the APAC region will experience a transformation in the form of intelligent healthcare and next-generation.
According to the National Academy of Medical Sciences (NAMS), breast cancer is one of the significant public health concerns in India. In June 2024, Fujifilm India and NM Medical launched a skill laboratory for advanced mammography training.
In November 2024, the Armed Forces Medical College (AFMC) launched a digital mammography centre for breast cancer screening.
The International Interdisciplinary Journal of the American Cancer Society reported that the absolute number of breast cancer cases reaches up to 400,000 every year. China adopted cancer screening projects for women and early cancer screening programs for breast and cervical cancers. Research is underway that aims to determine the best screening methods for Chinese women.
The R&D process for tomosynthesis or tomo mammography involves hardware innovation, advanced software and AI integration, and expanded clinical applications. The R&D process phases include fundamental research, concept validation, prototype development, pre-clinical testing, clinical evaluation, clinical trials, market launch, and post-market surveillance.
Key Players: Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation, iCAD, Inc.
The distribution to hospitals is managed through different channels like direct-to-hospital sales, specialized medical equipment distributors, government-led initiatives, and specialty clinics. The in-vitro diagnostic devices, single-use surgical items, home healthcare products, etc., are associated with distribution to pharmacies.
Key Players: GE Healthcare, Hologic, Inc., Fujifilm Corporation, Siemens Healthineers, Canon Medical Systems, etc.
These services and solutions include integrated care, clinical services, management of patient comfort, anxiety, financial assistance, insurance navigation, patient education, and advocacy.
Key Players: Hologic, Inc., GE Healthcare, Siemens Healthineers, Fujifilm Holdings Corporation.
In November 2024, Toshio Takiguchi, President and CEO of Canon Medical Systems, announced a global initiative named ‘Screen for Life, Breathe with Hope’, which is designed to advance lung cancer screening efforts, promote early detection, and reduce lung cancer-related mortality.
By Product/System Type
By Imaging Detector/Hardware Technology
By Software/Post-Processing
By Integration/Interoperability
By Region
September 2025
September 2025
September 2025
September 2025